The Role of Glycosphingolipids in Diabetic Retinopathy

描述（由申请人提供）：糖尿病视网膜病变是糖尿病的一种使人衰弱的并发症，也是视力丧失的主要原因;然而，导致视力丧失的基本机制仍不明确。在我们先前资助的R 03基金中，我们假设鞘脂代谢的改变有助于糖尿病并发症，包括视网膜内的神经元凋亡。我们现在已经发表了功能失调的鞘糖脂代谢可能有助于糖尿病的代谢应激，恢复正常鞘糖脂代谢的治疗策略可能是治疗糖尿病视网膜病变的可行方法。具体地说，我们发表的和初步的数据表明，葡萄糖神经酰胺在体内糖尿病视网膜内积累，葡萄糖神经酰胺合酶的抑制提高了高血糖条件下的胰岛素敏感性，并减少了炎症性精氨酸诱导的视网膜神经元细胞死亡。在本建议中，我们将这些观察扩展到更多的机制研究。我们现在假设高血糖和/或炎症直接调节葡糖神经酰胺合酶活性，导致葡糖神经酰胺的积累。我们还假设，靶向葡糖神经酰胺合酶的β-内酰胺酶可能对糖尿病视网膜病变有治疗作用。糖尿病视网膜病变的病因是什么？我们采用脂质组学，一个复杂的质谱策略，量化糖尿病视网膜内的脂质代谢物的质量。初步和已发表的数据已确定1型糖尿病模型中的鞘糖脂代谢功能障碍。我们研究的临床相关性在于这些脂质组学研究已经确定葡萄糖神经酰胺合酶为糖尿病并发症的“可用药”靶点。

DESCRIPTION (provided by applicant): Diabetic retinopathy is a debilitating complication of diabetes and a leading cause of vision loss; however the fundamental mechanisms contributing to vision loss remain undefined. In our previously funded R03 grant, we hypothesized that altered sphingolipid metabolism contributes to diabetic complications including neuronal apoptosis within the retina. We have now published that dysfunctional glycosphingolipid metabolism may contribute to metabolic stress in diabetes and therapeutic strategies to restore normal sphingolipid metabolism may be a viable approach for treatment of diabetic retinopathy. Specifically, our published and preliminary data demonstrate that glucosylceramide accumulates within diabetic retinas in vivo and that inhibition of glucosylceramide synthase improves insulin sensitivity under hyperglycemic conditions and diminishes inflammatory cytokine-induced retinal neuronal cell death. In the present proposal, we extend these observations to more mechanistic studies. We now hypothesize that hyperglycemia and/or inflammation directly regulate glucosylceramide synthase activity, resulting in accumulation of glucosylceramides. We also hypothesize that pharmacologically targeting glucosylceramide synthase may be therapeutic for diabetic retinopathy. PUBLIC HEALTH RELEVANCE: The underlying cause of diabetic retinopathy is still unknown. We have employed lipidomics, a sophisticated mass spectroscopy strategy, to quantify the mass of lipid metabolites within the diabetic retina. Preliminary and published data have identified dysfunctional glycosphingolipid metabolism in models of Type 1 diabetes. The clinical relevance of our studies is that these lipidomic studies have identified glucosylceramide synthase as a "drugable" target for diabetic complications.